GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PSNL
Personalis provides cutting-edge genomic data for oncology drug development. Its stock price is a bet on the growth of personalized medicine. The chart reflects the company's reliance on contracts with major pharmaceutical and government agencies.
Share prices of companies in the market segment - Cancer cure
Personalis, Inc. provides advanced genomic data and analytics for the development of personalized cancer treatments. We classify it in the Cancer Treatment segment because its platform is helping create next-generation oncology therapies. The chart below illustrates the dynamics of this science-intensive and innovative sector.
Broad Market Index - GURU.Markets
Personalis is an oncology company that provides advanced genome sequencing services for the development of personalized cancer treatments. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Personalis' performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
PSNL - Daily change in the company's share price PSNL
The volatility of Personalis, a cancer genomics company, is measured by change_co. It reflects sensitivity to contracts and scientific breakthroughs. This metric is a key component of formulas on System.GURU.Markets for biotech sector analysis.
Daily change in the price of a set of shares in a market segment - Cancer cure
Personalis, Inc. is a genomic diagnostics company. This chart highlights the sector's high volatility. Comparing it to PSNL, which focuses on oncology, helps assess how sensitive its business is to the introduction of new tests.
Daily change in the price of a broad market stock, index - GURU.Markets
Personalis is a company specializing in genomic sequencing for oncology. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below shows the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PSNL
Personalis, Inc.'s year-over-year performance tells the story of personalized oncology. The company's market capitalization over the past 12 months reflects demand from pharmaceutical companies for its tumor genomic analysis platforms. Large contracts to support clinical trials of new drugs are a fundamental driver of its growth.
Annual dynamics of market capitalization of the market segment - Cancer cure
Personalis, Inc. is a genomics company providing cutting-edge oncology solutions. Its platform enables in-depth tumor analysis. The graph shows how its technological leadership, dependence on pharmaceutical R&D budgets, and competition in the sector influence its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Personalis, with its genome analysis platform, is a speculative bet on the future of medicine. Its stock price isn't tied to economics, but rather driven by scientific breakthroughs and partnerships. The chart tells the story of investors' faith in the future of personalized oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PSNL
The value of Personalis, a cancer genomics company, depends on the R&D cycles of the pharmaceutical industry. The monthly fluctuations in the chart reflect the demand for its sequencing services from pharmaceutical companies conducting clinical trials, its primary source of revenue.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Personalis provides cutting-edge genomic data for the development of personalized cancer treatments. Their platform helps understand the unique characteristics of each patient's tumor. The graph below illustrates the overall dynamics in the oncology research sector, where precision medicine and genomics are playing an increasingly important role.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks in the genomics space are betting on the future of personalized medicine. The chart below shows investors' overall risk appetite. Is Personalis, Inc. following the market's growth, or are its scientific breakthroughs creating their own trend?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PSNL
Personalis, a company specializing in genomic sequencing for oncology, is extremely sensitive to scientific news. Its weekly stock price reflects new contracts with pharmaceutical companies and data on the effectiveness of its platform.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Personalis, like other companies in the genomic sequencing sector, is dependent on overall trends in oncology and personalized medicine. Growing R&D budgets in this field are a common driver for all. The graph will show whether PSNL is ahead of the industry, confirming demand for its unique platform for immune system analysis.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Personalis, as a biotech company, often ignores general market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials and contracts with pharmaceutical companies. The chart below clearly demonstrates how PSNL shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
PSNL - Market capitalization of the company PSNL
Personalis's market cap is a bet on deep genomic analysis for oncology. The company provides sequencing services for pharmaceutical companies and clinical trials. Its valuation reflects how investors view the demand for more accurate and comprehensive data for developing personalized cancer treatments.
PSNL - Share of the company's market capitalization PSNL within the market segment - Cancer cure
Personalis provides cutting-edge genomic data for the development of personalized cancer treatments. Its market capitalization reflects its technological leadership in oncogenomics. The chart below shows how investors value its platform and its application in clinical trials and diagnostics.
Market capitalization of the market segment - Cancer cure
Personalis provides cutting-edge genomic data for the development of personalized cancer therapies. The chart below shows the market capitalization of the oncology sector. This is an estimate of the market, where in-depth tumor DNA analysis is key to the development of effective drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Personalis is a company providing cutting-edge genomic data for the development of personalized cancer treatments. The company's market capitalization reflects its role in the personalized medicine revolution. Its share of the economy reflects the weight of its technologies that help understand the unique genetic characteristics of each patient's tumor to select the best therapy.
Book value capitalization of the company, segment and market as a whole
PSNL - Book value capitalization of the company PSNL
Personalis is a cutting-edge genomics laboratory. It comprises sophisticated DNA and RNA sequencing equipment, robotic systems, and, most importantly, an information platform for analyzing massive amounts of genetic data in oncology. The chart below shows how the company has invested in building its high-tech service base.
PSNL - Share of the company's book capitalization PSNL within the market segment - Cancer cure
Personalis, Inc. provides genome sequencing services, leveraging its state-of-the-art laboratory. This high-tech infrastructure is its primary physical asset. The S_BCap_Seg chart shows its share of the physical assets in the genomic analysis sector.
Market segment balance sheet capitalization - Cancer cure
Against the backdrop of the capital-intensive pharmaceutical industry, Personalis has chosen the diagnostics industry. Its business requires a unique resource base—advanced genomic analysis laboratories. The graph illustrates the scale of the industry in which Personalis occupies its high-tech, less capital-intensive niche.
Book value of all companies included in the broad market index - GURU.Markets
Personalis provides cutting-edge genome sequencing services for oncology and immunology. The company's assets are high-tech laboratories that "read" the genetic code to create personalized drugs. The chart below illustrates the material weight of this genetic data "factory."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PSNL
Personalis's balance sheet lies in its cutting-edge genetic labs. The market values it at a premium, viewing it not just as a service but as an "information hub" for developing personalized cancer treatments. The chart shows how much more valuable genomic data is than the equipment itself.
Market to book capitalization ratio in a market segment - Cancer cure
Personalis, Inc. provides advanced genome sequencing services for oncology and research. Its value lies in its technology and data. This chart shows how its market valuation, reflecting the potential for personalized medicine, is many times greater than its book value of assets (laboratories).
Market to book capitalization ratio for the market as a whole
Personalis is a company focused on genomic sequencing and analytics for oncology. Its platform helps develop personalized cancer treatments. The company's value lies in its technology and data. The chart shows how investors view its scientific potential and role in the future of personalized medicine, which is reflected in its high valuation.
Debts of the company, segment and market as a whole
PSNL - Company debts PSNL
Personalis, a company specializing in genomic sequencing for oncology, uses raised capital to fund its research and commercial operations. This chart shows how the company spends its funds on developing more accurate diagnostic tests and providing services to pharmaceutical companies for their clinical trials.
Market segment debts - Cancer cure
Personalis provides cutting-edge genome sequencing services for oncology and research. This is a capital-intensive field, requiring expensive equipment and ongoing investment in R&D. This chart shows how the company's debt policy reflects its funding needs for expanding laboratory capacity and developing new diagnostic tests.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PSNL
Personalis provides cutting-edge genomic data for the development of personalized medicine. It's a science-intensive business, requiring expensive equipment and ongoing research. This chart shows how much of its innovation the company finances with debt, reflecting its commitment to the future of oncology.
Market segment debt to market segment book capitalization - Cancer cure
Personalis, a company providing advanced genomic solutions for oncology and immunotherapy. This chart compares its debt load to the overall market capitalization of the entire sector. It shows how the company finances its complex technology platform, which aids in the development of personalized cancer treatments.
Debt to book value of all companies in the market
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. It is a knowledge-intensive business, requiring significant investment in technology and research. This market debt chart provides insight into the overall availability of capital, which is critical for companies like Personalis working at the forefront of oncology.
P/E of the company, segment and market as a whole
P/E - PSNL
This chart from Personalis, Inc., a company providing advanced genomic solutions for oncology, shows the valuation of its technology platform. Profits may not be forthcoming. The metric reflects not current revenue, but investor expectations regarding future demand for personalized medicine and the use of its data in drug development.
P/E of the market segment - Cancer cure
Personalis, Inc. is a cancer genomics company. It provides comprehensive tumor genomic data to aid in the development of personalized therapies. This chart illustrates the average valuation in the oncology research sector, where investors value technologies that advance precision medicine.
P/E of the market as a whole
Personalis provides advanced genomic sequencing and analysis services for oncology and drug development. This chart shows the overall sentiment in the biotech sector. Comparisons help us understand whether Personalis is perceived as a key player in personalized medicine or whether its valuation is moving in line with other biotech service companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PSNL
A chart from Personalis, Inc., a company providing genomic sequencing services for oncology, shows market expectations for future growth. It reflects analysts' faith in personalized medicine and the demand for its platform from pharmaceutical companies developing targeted cancer therapies.
%20P%2FE%20PSNL&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PSNL&v=1772627550945 "Chart of the company's future (projected) P/E PSNL")
Future (projected) P/E of the market segment - Cancer cure
Personalis, Inc. provides advanced genomic sequencing services for oncology and immunotherapy. This chart shows average expectations for the biotech sector. PSNL's position may indicate how investors view its technology platform and its role in advancing personalized medicine and developing new cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772627550968 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Personalis provides cutting-edge genomic data for oncology. The company is at the forefront of science. Its valuation depends on technological breakthroughs and contracts with pharmaceutical companies. Overall market sentiment in this chart influences capital availability, but not the scientific merit of its developments.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772627550983 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PSNL
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. This chart reflects its business at the intersection of genetics and oncology. The company's revenue depends on contracts with pharmaceutical companies that use its tumor analysis platform during clinical trials of new drugs.
Profit of companies in the market segment - Cancer cure
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. Profitability in the oncology sector, as this chart shows, is increasingly shifting toward personalized approaches. For PSNL, the growing demand for its platform from pharmaceutical companies reflects the global trend toward developing drugs that target specific genetic mutations.
Overall market profit
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. Its clients are biopharmaceutical companies. Demand for Personalis's services depends on the level of R&D investment in the industry, which, in turn, is linked to the overall market situation, as reflected in this chart. Market growth facilitates research funding.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PSNL
Personalis provides cutting-edge genomic data for the development of personalized cancer treatments. This chart shows analysts' forecasts for future revenue, which are driven by contracts with pharmaceutical companies and growth in the oncology research market. This estimate reflects demand for its unique analytics platform.
%20profit%20of%20the%20company%20PSNL&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PSNL&v=1772627551061 "Graph of future (projected) profit of the company PSNL")
Future (predicted) profit of companies in the market segment - Cancer cure
Personalis, Inc. provides advanced genome sequencing and data analysis services for the development of personalized cancer treatments. The company operates at the forefront of oncology. This chart shows the revenue forecast for the cancer treatment sector, reflecting market expectations for the development of personalized medicine and the demand for advanced genetic diagnostics.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772627551068 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Personalis, Inc. provides cutting-edge genomic data for oncology drug development. Demand for its services depends on pharmaceutical companies' R&D budgets. While cancer research is a long-term priority, during periods of severe economic downturn, even large pharmaceutical companies may reassess their budgets, which could slow Personalis's growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772627551086 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PSNL
Personalis, Inc. provides advanced genome sequencing services for cancer research and personalized therapy development. Its revenue depends on contracts with pharmaceutical companies and research institutes. The chart shows how the market values its technology platform, betting on the growth of the personalized medicine market.
P/S market segment - Cancer cure
Personalis, Inc. provides advanced genomic data and analytics for the development of personalized cancer treatments. The chart shows the average revenue estimate in the biotech sector. It helps understand how highly investors value its technology platform and its role in oncology development compared to other diagnostics companies.
P/S of the market as a whole
Personalis, Inc. provides advanced genome sequencing services for the development of personalized cancer treatments. Its revenue is dependent on biopharmaceutical companies' research expenditures. This chart helps understand the market's valuation of a company whose technologies play a key role at the forefront of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PSNL
Personalis, Inc. provides advanced genome sequencing services for oncology and research. The chart reflects investor assessments of its role in personalized medicine. The company's value is determined by projected future revenue from its analytics platforms, which aid in the development of new cancer treatments.
%20P%2FS%20PSNL&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PSNL&v=1772627551216 "The graph of the company's future (projected) P/S PSNL")
Future (projected) P/S of the market segment - Cancer cure
Personalis, Inc. provides advanced genomic data for the development of personalized cancer treatments. The data presented shows the median estimated future revenue for cancer treatment companies. This allows investors to assess the market perception of demand for the Personalis platform from pharmaceutical companies and its role in the advancement of oncology.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772627551284 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. Its business is at the forefront of medicine. This indicator of overall revenue expectations is irrelevant. PSNL's success depends on demand for its services from pharmaceutical companies and advances in oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772627551331 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PSNL
Personalis provides advanced genomic sequencing services for oncology and research. Its revenue, reflected in this chart, is generated through contracts with pharmaceutical companies and research centers. Sales growth reflects the high demand for its accurate analytical data, which aids in the development of new cancer treatments.
Sales of companies in the market segment - Cancer cure
Personalis, Inc. provides advanced genomic sequencing and analysis services for the development of personalized cancer treatments. Their platform provides a detailed understanding of the tumor's genetic profile and the patient's immune system. This chart shows total revenue in the sector, reflecting the growth of the personalized medicine and oncology market.
Overall market sales
Personalis, Inc. provides cutting-edge genomic solutions for oncology and other diseases. This chart reflects the state of the economy, but for PSNL, investments in personalized medicine are crucial. The company's success depends on demand from pharmaceutical companies for its drug discovery and diagnostics platform, which is at the cutting edge of science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PSNL
Personalis, Inc. provides advanced genomic data for the development of personalized cancer treatments. Demand for its services is driven by the growth of the oncology research and development market for pharmaceutical companies. This chart shows the expected increase in sequencing orders from its key biopharma clients.
%20sales%20of%20the%20company%20PSNL&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PSNL&v=1772627551447 "Schedule of future (projected) sales of the company PSNL")
Future (projected) sales of companies in the market segment - Cancer cure
Personalis, Inc. provides advanced genome sequencing and data analysis services for the development of personalized cancer treatments. Its platform helps create customized vaccines and therapies. The chart shows forecasts for the cancer treatment sector. Personalis' growth depends on the development of personalized medicine and oncology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772627551459 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Personalis, Inc. provides advanced genomic data for the development of personalized oncology. Demand for its services depends on research and development (R&D) budgets in the pharmaceutical industry. This trend, reflecting overall economic confidence, influences the willingness of large pharmaceutical companies to invest in innovative platforms for the development of new drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772627551481 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PSNL
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. The company's profitability depends on demand for its analytical services from pharmaceutical companies. This chart shows how the company is translating its unique scientific capabilities into a commercially viable product.
Market segment marginality - Cancer cure
Personalis, Inc. provides advanced genomic data for the development of personalized cancer treatments. This chart shows the average profitability in the biotech sector. Its deep expertise in immuno-oncology and partnerships with pharmaceutical companies give it the potential to achieve profitability significantly above the industry average.
Market marginality as a whole
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. It is a science-intensive business serving pharmaceutical companies and research centers. This total revenue chart vividly illustrates the difference between companies creating tools for the future of medicine and those making a profit today.
Employees in the company, segment and market as a whole
Number of employees in the company PSNL
Personalis is a genomics company specializing in oncology. Its team consists of lab technicians, bioinformaticians, and scientists. The growth in this graph reflects increased demand for its sequencing and data analysis services from pharmaceutical companies for their clinical trials.
Share of the company's employees PSNL within the market segment - Cancer cure
Personalis, Inc. provides cutting-edge genome sequencing services for oncology and research. This high-tech service requires both sophisticated laboratories and a team of bioinformaticians. This chart shows the company's share of specialists in the genomics niche, reflecting its scientific and technological weight in personalized medicine.
Number of employees in the market segment - Cancer cure
Personalis, Inc. provides advanced genomic sequencing and analysis services for oncology and immunotherapy. The growth of its highly qualified bioinformaticians and laboratory technicians, visible in the graph, reflects the growing demand for personalized medicine. The company is expanding its team to process more samples and develop new tests.
Number of employees in the market as a whole
Personalis, Inc. provides cutting-edge genomic data for cancer treatment development. Its business is at the forefront of science and relies on biotechnology investments, not on the overall employment shown in this chart. The company's value is determined by its technology platform and contribution to personalized medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PSNL (PSNL)
Personalis, Inc. provides genomic sequencing services. This is a high-tech service. This chart shows how the market values its unique technology platform and data. Value is created by sophisticated equipment and the expertise of a small team of scientists, resulting in a high cost per employee.
%20of%20the%20company%20PSNL%20(PSNL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PSNL-PSNL&v=1772627551594 "Chart of market capitalization per employee (in thousands of dollars) of the company PSNL (PSNL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Personalis, Inc. provides cutting-edge genomic data for the development of personalized cancer treatments. It's a science-intensive business, where the core value lies in the team's expertise and technology platform. This chart illustrates how investors value the company's intellectual capital per employee.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772627551602 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Personalis, Inc. provides advanced genomic data for the development of personalized cancer treatments. The chart shows its valuation in the genomics sector. The high cost per employee reflects the value of their sophisticated technology platform and data, which help pharmaceutical companies develop new drugs.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772627551612 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PSNL (PSNL)
Personalis, Inc. provides cutting-edge genomic data for oncology research, helping pharmaceutical companies develop cancer drugs. This graph shows the efficiency of their high-tech lab. It measures how much revenue each scientist and technician generates by performing complex genetic analysis. This is an indicator of the value of their data.
%20Chart%20PSNL%20(PSNL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PSNL-PSNL&v=1772627551632 "Company Profit Per Employee (in thousands of dollars) Chart PSNL (PSNL)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Personalis (PSNL) is a "service" biotech company (genomic analysis for oncology). This chart shows the benchmark for "Cancer Treatment" (Services). The average revenue per employee in this sector is a hybrid. The benchmark reflects both R&D (test development) and "service" (the operation of giant laboratories). It is a scalable but capital-intensive "laboratory" business.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772627551637 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Personalis (PSNL) provides advanced genome sequencing and data analysis services, primarily for oncology research and pharmaceutical companies. It's a knowledge-intensive laboratory service. This chart shows the profit (or loss, if in the R&D phase) generated by each scientist and technician providing complex analytical services.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772627551652 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PSNL (PSNL)
Personalis, Inc. provides cutting-edge genomic data for oncology. This chart shows how the company is commercializing its data-intensive platform. The growth in revenue per employee demonstrates strong demand from pharmaceutical companies for its drug discovery services, confirming the value of its data.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PSNL-PSNL&v=1772627551673 "Sales chart per company employee PSNL (PSNL)")
Sales per employee in the market segment - Cancer cure
Personalis (PSNL) provides advanced genomic sequencing (DNA analysis) services, primarily for oncology research and pharmaceutical companies. It's a high-tech service. This chart illustrates their knowledge-intensive model. PSNL's productivity depends on the throughput of their laboratories and their ability to sell sophisticated, high-value-added analytical services.
Sales per employee for the market as a whole
Personalis is a company providing cutting-edge genomic data for oncology. Their business is high-tech laboratory services and R&D. This metric measures the revenue generated by each employee (lab technician, scientist, data analyst). It reflects the value of their sophisticated analytics for pharmaceutical companies and clinics.
Short shares by company, segment and market as a whole
Shares shorted by company PSNL (PSNL)
Personalis (PSNL) is a company specializing in advanced genomics for oncology. They provide ultra-deep DNA and RNA analysis of tumors to aid in the development of personalized treatments. This chart highlights bearish bets. Are the bears doubting the widespread commercialization of their expensive tests or the high level of competition?
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PSNL-PSNL&v=1772627551756 "Short Shares Chart for the Company PSNL (PSNL)")
Shares shorted by market segment - Cancer cure
Personalis (PSNL) is a company that provides sequencing services (genomics and proteomics) to oncology researchers and pharmaceutical companies. This chart shows bets against the entire biotech sector. The rising bets against the industry reflect concerns that biotech and pharmaceutical companies will cut R&D budgets, which will directly reduce demand for Personalis's expensive assays.
Shares shorted by the overall market
Personalis provides cutting-edge genomic data for oncology research. Its clients are biotech and pharmaceutical companies. When this graph shows rising fears, a "venture winter" freezes biotech funding. This immediately hits R&D budgets, forcing Personalis' clients to cut research spending.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PSNL (PSNL)
Personalis provides genomic data for oncology research. Its business depends on pharmaceutical companies' R&D budgets. This chart, above 70, may reflect strong demand from biotech. Below 30, it's often associated with a "venture winter" and concerns about clients cutting their R&D budgets.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PSNL-PSNL&v=1772627551801 "RSI 14 indicator chart for the company's stock PSNL (PSNL)")
RSI 14 Market Segment - Cancer cure
Personalis (PSNL) is a cancer genomics company. It provides cutting-edge tumor sequencing (DNA/RNA analysis) services for pharmaceutical companies and clinical trials. This chart shows the overall sentiment in the molecular diagnostics and oncology sectors. It helps us understand whether PSNL's performance is part of the overall "overheating" in genomics or a result of its technology platform.
RSI 14 for the overall market
Personalis (PSNL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PSNL (PSNL)
Personalis (PSNL) is a company specializing in advanced cancer genomics. It provides sequencing services (NeXT Platform) to pharmaceutical companies (R&D) and develops diagnostic tests. This chart shows the average analyst forecast, reflecting their assessment of the demand for genomic data in R&D and the potential of the company's diagnostic tests.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PSNL-PSNL&v=1772627551843 "A chart showing analyst consensus forecasts for the expected stock price. PSNL (PSNL)")
The difference between the consensus estimate and the actual stock price PSNL (PSNL)
Personalis is a high-tech genomics company providing ultra-deep sequencing and tumor analysis for oncology research and drug development. This chart shows the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in their diagnostic platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PSNL-PSNL&v=1772627551847 "A chart showing the difference between the consensus forecast and the actual stock price. PSNL (PSNL)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Personalis (PSNL) is a company specializing in deep genome and transcriptome sequencing for oncology research and the development of personalized cancer vaccines. This chart shows general expectations for the cancer treatment sector. It reflects whether experts believe in a boom in personalized oncology.
Analysts' consensus forecast for the overall market share price
Personalis (PSNL) is a cancer genomics company providing deep analytics for R&D (pharma companies). This chart of overall market sentiment is important. Optimism = biotechs easily attracting funds and spending them on clinical trials (by ordering PSNL tests). Pessimism = venture winter = R&D freeze.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PSNL
Personalis is a high-tech oncology company. They specialize in deep tumor genome sequencing (cancer profiling) for pharmaceutical companies (R&D) and, increasingly, for personalized treatment selection (clinical trials). This chart evaluates their scientific platform. It reflects their transition from an R&D service to a more scalable clinical diagnostics business.
AKIMA Market Segment Index - Cancer cure
Personalis (PSNL) is a high-tech diagnostics company; it is a pioneer in deep genome sequencing (NeXT Platform) for oncology, providing R&D services (B2B) to pharmaceutical companies. This summary metric evaluates R&D. The graph shows the sector average. This is a benchmark: how does this high-tech (R&D services) model (PSNL) differentiate it from the average competitor?
The AKIM Index for the overall market
Personalis is a genomics company specializing in deciphering complex cancer data for biopharma and clinical applications. This chart, reflecting the market average, provides context. It helps us assess how this scientific story, dependent on oncology research budgets, fits into the context of overall economic trends.
